ATC Group: L02BX Other hormone antagonists and related agents

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L02BX in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L02 Endocrine therapy
3 L02B Hormone antagonists and related agents
4 L02BX Other hormone antagonists and related agents

Group L02BX contents

Code Title
L02BX01 Abarelix
L02BX02 Degarelix
L02BX03 Abiraterone

Active ingredients in L02BX

Active Ingredient Description

Abarelix is a synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. Abarelix is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.


Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor. Specifically, abiraterone selectively inhibits the enzyme 17α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in and is required for androgen biosynthesis in testicular, adrenal and prostatic tumour tissues. CYP17 inhibition also results in increased mineralocorticoid production by the adrenals.


Degarelix is a selective gonadotrophin releasing-hormone (GnRH) antagonist that competitively and reversibly binds to the pituitary GnRH receptors, thereby rapidly reducing the release of the gonadotrophins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), and thereby reducing the secretion of testosterone (T) by the testes.


Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to GnRH receptors in the anterior pituitary gland preventing native GnRH from binding and signalling the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Consequently, the production of testosterone from the testes is reduced.

Related product monographs

Title Information Source Document Type  
FIRMAGON Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
ORGOVYX Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
ORGOVYX Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
ZYTIGA Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ZYTIGA Tablet European Medicines Agency (EU) MPI, EU: SmPC